Physician profile
Arkady Stern
NPI 1033198882
$6,292.89
in general payments reported to CMS, 2019-2025
45 companies · $812 in 2025
The $812 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $1,078 · 2021: $1,380 · 2022: $559 · 2023: $656 · 2024: $708 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $590.25 | 2021-2025 | Qulipta, Linzess, Viberzi |
| Pfizer INC. | $469.00 | 2019-2024 | |
| Amarin Pharma, INC. | $418.81 | 2019-2022 | |
| Astellas Pharma US INC | $338.93 | 2019-2021 | |
| Axsome Therapeutics, INC. | $327.38 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $323.40 | 2020-2025 | Trelegy Ellipta |
| Amgen INC. | $309.81 | 2019-2025 | Tepezza, Repatha, Otezla |
| Novo Nordisk INC | $224.60 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.54 | 2021-2025 | |
| Ardelyx, INC. | $170.32 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $156.13 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.27 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $151.31 | 2023 | Evkeeza |
| Lilly USA, LLC | $144.84 | 2020-2025 | Mounjaro, Zepbound |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.